BioPharmaBrief covers the science, the strategy, and the capital advancing biotech and pharma.
Our stories span discovery, clinical development, partnerships, financings, and the strategic decisions that shape what happens next. We are most interested in how those threads connect, because a scientific result and a strategic choice are rarely separate events for long.
Our editors have built their careers on both sides of that work, at the bench and in the rooms where companies chart their course, across three decades of progress in this field and squarely in the middle of what is happening now. That depth is what lets us find the nuance others move past: the finding in the data that deserves more attention than it received, the detail in an announcement that adds real context, the development whose significance becomes clear only when set against everything that came before it.
We publish for the people building these companies, funding them, and following them closely. Come see what we’re seeing.
Editorial independence:
No one associated with BioPharmaBrief or Jon Nugent Communications holds any ownership position in the companies we cover. Client, former client, and prospective client relationships are disclosed within the relevant article.